ESMO Breast Cancer Virtual Meeting | Conference

Frontline Datopotamab Deruxtecan/Durvalumab Combo Elicits Encouraging Responses in TNBC

May 19th 2022

The combination of the TROP2-directed antibody-drug conjugate datopotamab deruxtecan and durvalumab showcased early activity with acceptable safety when used as first-line treatment in patients with locally advanced or metastatic triple-negative breast cancer, according to data from the phase 1b/2 BEGONIA trial.

Entrectinib Continues to Yield Promising Data in NTRK Fusion–Positive Breast Cancer

May 11th 2022

Entrectinib produced deep and durable responses in patients with breast cancer harboring NTRK fusions.

Abemaciclib Plus Endocrine Therapy Elicits Efficacy in High-Risk, HR+ Early Breast Cancer Regardless of Menopausal Status

May 10th 2022

The addition of abemaciclib to endocrine therapy improved invasive disease-free survival and distant relapse-free survival vs endocrine therapy alone in patients with high-risk, hormone receptor–positive, HER2-negative, early-stage breast cancer, irrespective of menopausal status.

Nivolumab Plus Trastuzumab Deruxtecan Provides No Perceptible Clinical Benefit Over ADC Alone in Advanced HER2+ Breast Cancer

May 9th 2022

The addition of nivolumab to trastuzumab deruxtecan did not result in a marked clinical benefit in patients with locally advanced unresectable or metastatic HER2-positive breast cancer.

HER2 Expression Is a Key Determinant of Trastuzumab Deruxtecan Activity

May 8th 2022

HER2 expression appeared to be a significant predictor for response to fam-trastuzumab deruxtecan-nxki, according to findings from a biomarker analysis of patients with metastatic breast cancer in the phase 2 DAISY trial.

Adjuvant Abemaciclib Plus Endocrine Therapy Has Robust Efficacy in monarchE Cohort of High-Risk, HR+ Breast Cancer

May 6th 2022

The addition of adjuvant abemaciclib to endocrine therapy resulted in a clinically meaningful reduction in the risk of developing invasive disease, particularly incurable distant metastatic disease, in patients with high-risk, hormone receptor–positive, HER2-negative, early breast cancer who comprised cohort 1 of the phase 3 monarchE trial.

Pembrolizumab Plus Chemotherapy Does Not Significantly Affect QOL in PD-L1+ TNBC

May 6th 2022

The addition of pembrolizumab to chemotherapy led to significant survival benefits without substantial deterioration in health-related quality of life among patients with treatment-naïve, PD-L1–positive advanced triple-negative breast cancer according to results from the phase 3 KEYNOTE-355 trial.

Evidence Grows to Support Trastuzumab Deruxtecan in Patients With HER2+ Breast Cancer and Active Brain Metastases

May 6th 2022

Nearly all patients with HER2-positive breast cancer with brain metastases who received fam-trastuzumab deruxtecan-nxki elicited benefit, according to data from a primary outcome analysis of the phase 2 TUXEDO-1 trial.

Alpelisib Plus Endocrine Therapy Yields Similar PFS Benefits in Subgroup Analysis of PIK3CA-Mutated, HR+ Breast Cancer

May 6th 2022

The combination of alpelisib plus endocrine therapy elicited a clinical benefit across all subgroups of patients with hormone receptor–positive, HER2-negative advanced breast cancer with PIK3CA mutations.

Trastuzumab Deruxtecan Maintains QOL and Global Health Status in HER2+ Metastatic Breast Cancer

May 6th 2022

Overall health status and quality of life were maintained among patients with HER2-positive metastatic breast cancer who were treated with fam-trastuzumab deruxtecan-nxki compared with those who received ado-trastuzumab emtansine.

Sacituzumab Govitecan Maintains Clinical Benefit Across HER2 Expressions in TNBC

May 5th 2022

Sacituzumab govitecan-hziy maintained clinical benefit in patients with metastatic triple-negative breast cancer regardless of HER2 expression according to a post hoc analysis of the phase 3 ASCENT trial.

Maintained Survival Benefit Supports Frontline Ribociclib/Fulvestrant Combo in Advanced HR+ Breast Cancer

May 5th 2022

The addition of ribociclib to fulvestrant continued to significantly prolong overall survival, delayed time to second disease progression, and improved chemotherapy-free survival vs placebo plus fulvestrant in the first-line treatment of patients with advanced hormone receptor–positive, HER2-negative breast cancer.

Dr. de Ligt on Using Symptom Burden to Tailor Follow-Up Care in Breast Cancer Survivors

May 8th 2021

Kelly de Ligt, PhD, discusses subgroups of symptom burden seen in breast cancer survivors.

Dr. Dang on Cardiac Safety With Pertuzumab/Trastuzumab in Early-Stage HER2+ Breast Cancer

May 8th 2021

Chau T. Dang, MD, discusses the safety profile of pertuzumab plus trastuzumab in patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer.

High-Grade ILD Prevention With Trastuzumab Deruxtecan Includes Early Detection, Optimal Management in HER2+ Metastatic Breast Cancer

May 8th 2021

Effective early detection and optimal management are critical in preventing high-grade interstitial lung disease, a treatment-related adverse effect of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic breast cancer.

HER2+ Breast Cancer With Immune-Related Gene Signatures May Be Eligible for De-Escalation Approaches

May 8th 2021

Distinct gene signatures, with the exception of estrogen receptor signaling and BRCAness, are associated with pathologic complete response and invasive disease-free survival, in patients with HER2-positive breast cancer who received trastuzumab and pertuzumab alone or in combination with paclitaxel.

Dr. Powell on the Risk of ILD with Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 8th 2021

Charles Powell, MD, MBA, discusses the risk of interstitial lung disease in patients with HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan.

Datopotamab Deruxtecan Shows Encouraging Preliminary Safety, Efficacy in TNBC

May 8th 2021

The differentiated TROP2-directed antibody-drug conjugate datopotamab deruxtecan was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer.

Retesting for HER2 Upon Breast Cancer Relapse May Provide New Therapeutic Opportunities

May 8th 2021

Approximately 30% of breast cancer tumors can covert from, or to, HER2-low status, underscoring the need to retest for HER2 expression upon relapse.

Bachelot Spotlights Impact of Tucatinib for CNS Metastases in HER2+ Breast Cancer

May 8th 2021

Thomas Bachelot, MD, discussed how to approach treatment of patients with HER2-positive breast cancer and CNS metastases and the impact of tucatinib in this population.